Clinical Trials

  • Principal Investigator:

    Stergios Zacharoulis, MD
    The purpose of this study is to find out more about how the study drug called talimogene laherparepvec will be used in children/adolescents/young adults with advanced solid tumors not involving the central nervous system that are available for direct injection. This is a phase 1 study, multicenter, open-label study, that means all subject enrolled in the study will be assigned talimogene laherparepvec. The study drug is a genetically modified virus. The virus' genes were modified in a laboratory to make the virus active in the tumor cell but not in normal cell. Talimogene laherparepvec is...
  • Principal Investigator:

    Alice Lee, MD
    This study will enroll children from 6 months to 17 years old that have solid tumor cancers or lymphoma (cancer of the cells in the lymph nodes, part of the body's immune system). The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475) as well as look for the highest dose of pembrolizumab that can be given safely without serious side effects. This study will also attempt to find out how pembrolizumab is absorbed and broken down and determine how treatment with pembrolizumab may benefit children with cancer.
  • Principal Investigator:

    Meyer Kattan, MD
    The reason for this nationwide study is to help us learn if treatment with German cockroach extract, given as allergy shots, given along with standard asthma care makes children less likely to have asthma symptoms. The study will take up to 36 months. Study visits will include questionnaires, a physical examination, an allergy skin test, breathing tests, and blood, nasal collections, and allergy shots. You will be reimbursed for each completed study visit and your child will receive a gift.
  • Principal Investigator:

    Wendy Kay Chung, MD
    Several children are born with birth defects every day. Through extensive genetic research, we have learned over the years that there are genetic factors that can contribute to the occurrence of some of these defects, especially in children with more than one congenital defect. However, the underlying genetic causes of many birth defects still remain unknown. The goal of this study is to use a sophisticated technology called whole exome/genome sequencing to identify underlying genetic causes of surgical birth defects. The identification of such genes, and examination of their structure and...
  • Principal Investigator:

    Wendy Kay Chung, MD
    CARE is a new research initiative that aims to investigate the underlying genetic causes of various birth defects. By identifying the cause of these defects, we hope to be able to better understand their natural history which may ultimately lead to better treatment and management. Knowing the genetic causes of birth defects also allows us to assess the hereditary risk of the defect in a family. The study is free and involves submission of a blood or saliva sample from a child with a birth defect and both parents. If you have a child with a birth defect and would be interested in enrolling,...
  • Principal Investigator:

    Dani Dumitriu, MD
    The goal of this study is to address differences in health outcomes of newborns born to COVID positive versus case-matched COVID negative mothers, as well as mothers who gave birth immediately prior to the pandemic arriving in NYC (February 2020) through review of charts and surveys with mothers. Additionally, the study will distribute a survey to physicians and other healthcare workers involved in newborn care to ask them about their clinical practices during the pandemic.
  • Principal Investigator:

    Dani Dumitriu, MD
    The goal of this study is to address differences in health outcomes of newborns born to COVID positive versus case-matched COVID negative mothers, as well as mothers who gave birth immediately prior to the pandemic arriving in NYC (February 2020) through review of charts and surveys with mothers. Additionally, the study will distribute a survey to physicians and other healthcare workers involved in newborn care to ask them about their clinical practices during the pandemic.
  • Principal Investigator:

    Wendy Kay Chung, MD
    Each year more than 1,000 babies in the United States are born with a Congential Diaphragmatic Hernia (CDH). For the majority of these babies, the cause of the CDH is unknown. DHREAMS (Diaphragmatic Hernia Research & Exploration; Advancing Molecular Science) study was created to improve the understanding of the molecular genetic basis of CDH. This National Institute of Health (NIH)-funded research team is composed of health care providers and researchers across the country, coordinated at Columbia University Medical Center. Multiple medical centers are enrolling individuals and families...
  • Principal Investigator:

    Rakesh Sahni, MD
    The purpose of this study is to see if the use of bubble nasal continuous positive airway pressure (NCPAP) at a pressure of 6-7 centimeters of water (cm H2O) in very low birth weight (VLBW) infants is associated with improved gas exchange without any related changes in vital signs.
  • Principal Investigator:

    Stephanie Levasseur, MD
    Although supraventricular tachycardia (SVT), including atrial flutter (AF), are the most common causes of intended in-utero fetal therapy, none of the medication used to date has been evaluated for their effects on the mother and her baby in a randomized controlled clinical trial (RCT). In the absence of such evidence, there is no consensus for the optimal management. The purpose of the FAST Research study is to improve the care of pregnancies affected by AF or SVT. The aim of the FAST Registry is to record the treatment your doctor prescribes, your ongoing care, and the outcome of your...

Pages